Skip to main content
. Author manuscript; available in PMC: 2020 Apr 1.
Published in final edited form as: Gynecol Oncol. 2019 Jan 25;153(1):127–134. doi: 10.1016/j.ygyno.2019.01.015

Figure 3. HR-Deficiency status, BRCA1/BRCA2 mutation status, and response to ABT-767 among ovarian cancers.

Figure 3.

Archival tissue from ovarian cancers in patients treated in the highest seven dose levels was assessed for HR-deficiency (A) and sequenced for BRCA1/BRCA2 mutations (B).